Skip to content

Geron GERN Total costs & expenses

Total costs & expenses at other companies

Exelixis logo
ExelixisEXEL
$359.47M-2.5%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$103.61M+38.3%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$732.3M-23.2%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Incyte logo
IncyteINCY
Gilead Sciences logo
Gilead SciencesGILD

Segments

By segment

See full
Reportable Segment$1.7M+41.7%

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$888.51M-8.6%
Enterprise value$973.78M-6.2%
P/S4.7×-174×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:OperatingCostsAndExpenses.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's total costs & expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's total costs & expenses?
Geron (GERN) reported total costs & expenses of $1.69M in Q1 2026.
How has Geron's total costs & expenses changed year-over-year?
Geron's total costs & expenses increased by 40.3% year-over-year, from $1.21M to $1.69M.
What does total costs & expenses mean?
This metric represents the aggregate sum of all operating and non-operating costs incurred by the company during a specific reporting period. It encompasses research and development investments, selling, general and administrative overhead, and any restructuring or impairment charges necessary to sustain business operations. Monitoring this figure allows investors to assess the company's overall cost structure and the efficiency of its capital deployment in support of its clinical development pipeline.